Cancer Therapeutics CRC/Canthera Discovery win CRA Award for Research Commercialisation
Posted: 28 April 2022 Canthera Discovery is delighted to announce that its predecessor, Cancer Therapeutics CRC, received the Cooperative Research Australia (CRA) Excellence in Innovation Award for Research Commercialisation at an award ceremony at Parliament House in Canberra…
Presentation at the Lucust Walk Stem Cell Tx Conference
Posted: 8 April 2022 Event Date: 12 April 2022 Dr Ian Nisbet Chief Operating Officer Held in partnership with Harvard Stem Cell Institute, this virtual one-day investor and partner conference will explore stem cell therapeutics in the areas…
Cartherics CEO Alan Trounson ranked among the world’s most prominent scientists
Posted: 4 April 2022 The respected scientific platform Research.com has published the 2022 Edition of its Ranking of Top 1000 Scientists in the area of Biology and Biochemistry. BioMelbourne Network Member Cartherics welcomes the findings. In a notice…
Research Australia’s response to the Federal Budget
Posted: 31 March 2021 See below for BioMelbourne Network Member Research Australia’s response to the 2022/23 Federal Budget. The rising cost of living has become a key election issue and this Budget delivers cash payments, extends tax relief…
AusBiotech’s AusBioNSW launched
Posted: 29 March 2022 AusBiotech is proud to launch AusBioNSW, a new peak industry membership body for NSW, to represent, connect, and promote NSW organisations doing business in and with the local, national and global life sciences economy.…
Almac Group support Agios’ road to FDA approval
Posted: 24 March 2022 BioMelbourne Network Member Almac Group is proud to confirm it has supported Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, in the clinical trial and rapid…
Neuren receives FDA approval
Posted: 23 March 2022 BioMelbourne Network Member, Neuren Pharmaceuticals, has received approval from the US Food and Drug Administration (FDA) to proceed with the Phase 2 trial of NNZ-2591 in PhelanMcDermid syndrome (PMS). The Investigational New Drug application…
Technovalia, Sypharma and BioNet announce Australian Vaccine Hub
Posted: 23 March 2022 Technovalia, Sypharma and BioNet announce the establishment of Genetis, the first Australian Vaccine Development and Manufacturing Hub for mRNA, DNA and recombinant vaccines. Establishment of the first end-to-end Australian capability for product development and…
Imagion Biosystems: Breast cancer first-in-human study update
Posted: 18 March 2022 Imagion Biosystems Limited, a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to provide this update on the progress of its first-in-human study for the MagSense HER2 breast cancer…
PRAXIS: Quality Management in Research Virtual Workshop
Posted: 15 March 2022 Learn how to improve your unit processes, minimise delays, and increase the quality of your research by enrolling into PRAXIS Australia’s Quality by Design virtual workshop. On completion, you will be able to: Explain…
Stable Cell Line for Production of PAT-DX3 Established
Posted: 2 March 2022 BioMelbourne Network Member Patrys Limited, a therapeutic antibody development company, is pleased to announce it has identified and selected an optimised stable cell line for production of its full-sized IgG deoxymab, PAT-DX3. This allows…
ENA Respiratory and COPD Foundation to Develop Pan-Antiviral Nasal Spray
Posted: 24 February 2022 ENA Respiratory, a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for pre- and post-exposure prophylaxis of respiratory viral infections, including COVID-19 in populations at-risk of complications, and the COPD Foundation, a…
